SE9602442D0 - Administration of pharmaceuticals - Google Patents

Administration of pharmaceuticals

Info

Publication number
SE9602442D0
SE9602442D0 SE9602442A SE9602442A SE9602442D0 SE 9602442 D0 SE9602442 D0 SE 9602442D0 SE 9602442 A SE9602442 A SE 9602442A SE 9602442 A SE9602442 A SE 9602442A SE 9602442 D0 SE9602442 D0 SE 9602442D0
Authority
SE
Sweden
Prior art keywords
extended
atpase
pharmaceuticals
administration
profile
Prior art date
Application number
SE9602442A
Other languages
English (en)
Swedish (sv)
Inventor
Christer Cederberg
George Sachs
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9602442A priority Critical patent/SE9602442D0/xx
Publication of SE9602442D0 publication Critical patent/SE9602442D0/xx
Priority to IL12754297A priority patent/IL127542A0/xx
Priority to TR1998/02647T priority patent/TR199802647T2/xx
Priority to DE69725860T priority patent/DE69725860T2/de
Priority to CA002257405A priority patent/CA2257405A1/en
Priority to US08/945,425 priority patent/US20010008900A1/en
Priority to EE9800435A priority patent/EE04606B1/xx
Priority to HU9901794A priority patent/HUP9901794A3/hu
Priority to PCT/SE1997/001098 priority patent/WO1997048380A1/en
Priority to BR9709838A priority patent/BR9709838A/pt
Priority to DK97930933T priority patent/DK0921787T3/da
Priority to CNB971955387A priority patent/CN1178648C/zh
Priority to NZ332990A priority patent/NZ332990A/xx
Priority to ES97930933T priority patent/ES2208921T3/es
Priority to UA99010150A priority patent/UA64715C2/uk
Priority to SI9730615T priority patent/SI0921787T1/xx
Priority to RU99101081/14A priority patent/RU2203662C2/ru
Priority to PT97930933T priority patent/PT921787E/pt
Priority to HK99103406.4A priority patent/HK1018590B/en
Priority to EP97930933A priority patent/EP0921787B1/en
Priority to JP10502822A priority patent/JP2000512993A/ja
Priority to AU34690/97A priority patent/AU726859B2/en
Priority to SK1655-98A priority patent/SK284204B6/sk
Priority to AT97930933T priority patent/ATE252885T1/de
Priority to CZ0420398A priority patent/CZ298213B6/cs
Priority to PL97330910A priority patent/PL189716B1/pl
Priority to YUP-566/98A priority patent/RS49590B/sr
Priority to IL127542A priority patent/IL127542A/en
Priority to IS4923A priority patent/IS2216B/is
Priority to NO19985964A priority patent/NO323295B1/no
Priority to US10/871,506 priority patent/US20050113418A1/en
Priority to US11/544,956 priority patent/US20070276007A1/en
Priority to US12/242,006 priority patent/US20090036494A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
SE9602442A 1996-06-20 1996-06-20 Administration of pharmaceuticals SE9602442D0 (sv)

Priority Applications (33)

Application Number Priority Date Filing Date Title
SE9602442A SE9602442D0 (sv) 1996-06-20 1996-06-20 Administration of pharmaceuticals
PL97330910A PL189716B1 (pl) 1996-06-20 1997-06-18 Zastosowanie inhibitora H+, K+-ATPazy
UA99010150A UA64715C2 (en) 1996-06-20 1997-06-18 Pharmaceutical composition with extended release of h+, k+-atpase inhibitor (variants) and method for enhancing inhibition of acid secretion in stomach
SI9730615T SI0921787T1 (en) 1996-06-20 1997-06-18 ADMINISTRATION REGIMEN OF H+,K+-ATPase INHIBITORS
DE69725860T DE69725860T2 (de) 1996-06-20 1997-06-18 PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN
CA002257405A CA2257405A1 (en) 1996-06-20 1997-06-18 Administration regimen of h+, k+-atpase inhibitors
US08/945,425 US20010008900A1 (en) 1996-06-20 1997-06-18 Administration of pharmaceuticals
EE9800435A EE04606B1 (et) 1996-06-20 1997-06-18 H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
HU9901794A HUP9901794A3 (en) 1996-06-20 1997-06-18 Administration regimen of h+,k+-atpase inhibitors
PCT/SE1997/001098 WO1997048380A1 (en) 1996-06-20 1997-06-18 ADMINISTRATION REGIMEN OF H+, K+-ATPase INHIBITORS
PT97930933T PT921787E (pt) 1996-06-20 1997-06-18 Regime de administracao de inibidores de atpase de h',k'
DK97930933T DK0921787T3 (da) 1996-06-20 1997-06-18 Indgivelsesdosering af H+, K+ -ATPase-inhibitorer
CNB971955387A CN1178648C (zh) 1996-06-20 1997-06-18 H+ 、k+ －atp酶抑制剂在制备用于增强抑制胃酸分泌的口服药物中的用途
NZ332990A NZ332990A (en) 1996-06-20 1997-06-18 oral pharmaceutical composition containing a H+, K+-atpase inhibitor having a extended blood plasma profile
ES97930933T ES2208921T3 (es) 1996-06-20 1997-06-18 Regimen de administracion de los inhibidores de la h+,k+-atpasa.
IL12754297A IL127542A0 (en) 1996-06-20 1997-06-18 Administration regimen of H+ K+ -ATPase inhibitors
RU99101081/14A RU2203662C2 (ru) 1996-06-20 1997-06-18 РЕЖИМ ВВЕДЕНИЯ ИНГИБИТОРОВ Н+, К+-АТФазы
HK99103406.4A HK1018590B (en) 1996-06-20 1997-06-18 Administration regimen of h+,k+-atpase inhibitors
BR9709838A BR9709838A (pt) 1996-06-20 1997-06-18 Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
TR1998/02647T TR199802647T2 (xx) 1996-06-20 1997-06-18 H+, K+-ATPaz inhibit�rlerinin administrasyon rejimi.
EP97930933A EP0921787B1 (en) 1996-06-20 1997-06-18 ADMINISTRATION REGIMEN OF H+,K+-ATPase INHIBITORS
JP10502822A JP2000512993A (ja) 1996-06-20 1997-06-18 Ｈ▲上＋▼，ｋ▲上＋▼−ａｔｐアーゼ阻害剤の投与計画
AU34690/97A AU726859B2 (en) 1996-06-20 1997-06-18 Administration regimen of H+, K+-ATPase inhibitors
SK1655-98A SK284204B6 (sk) 1996-06-20 1997-06-18 Použitie inhibítora H+, K+-ATPázy
AT97930933T ATE252885T1 (de) 1996-06-20 1997-06-18 Plan zur verabreichung von h+, k+-atpase inhibitoren
CZ0420398A CZ298213B6 (cs) 1996-06-20 1997-06-18 Lécivo pro zlepsení inhibice sekrece zaludecní kyseliny
YUP-566/98A RS49590B (sr) 1996-06-20 1998-12-09 Upotreba inhibitora h+,k+-atpaze za proizvodnju novih farmaceutskih preparata
IL127542A IL127542A (en) 1996-06-20 1998-12-13 H+, K+-ATPase INHIBITORS FOR USE IN IMPROVED INHIBITION OF GASTRIC ACID SECRETION
IS4923A IS2216B (is) 1996-06-20 1998-12-15 Meðferðaráform við inngjöf á H+,K+ -ATPasa-hemla
NO19985964A NO323295B1 (no) 1996-06-20 1998-12-18 Anvendelse av H+,K+-ATPase-inhibitorer for fremstilling av oralt administrerbare medikamenter for inhibering av magesyresekresjon
US10/871,506 US20050113418A1 (en) 1996-06-20 2004-06-18 Administration of pharmaceuticals
US11/544,956 US20070276007A1 (en) 1996-06-20 2006-10-05 Administration of pharmaceuticals
US12/242,006 US20090036494A1 (en) 1996-06-20 2008-09-30 Administration of Pharmaceuticals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9602442A SE9602442D0 (sv) 1996-06-20 1996-06-20 Administration of pharmaceuticals

Publications (1)

Publication Number Publication Date
SE9602442D0 true SE9602442D0 (sv) 1996-06-20

Family

ID=20403092

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9602442A SE9602442D0 (sv) 1996-06-20 1996-06-20 Administration of pharmaceuticals

Country Status (27)

Country Link
US (4) US20010008900A1 (cs)
EP (1) EP0921787B1 (cs)
JP (1) JP2000512993A (cs)
CN (1) CN1178648C (cs)
AT (1) ATE252885T1 (cs)
AU (1) AU726859B2 (cs)
BR (1) BR9709838A (cs)
CA (1) CA2257405A1 (cs)
CZ (1) CZ298213B6 (cs)
DE (1) DE69725860T2 (cs)
DK (1) DK0921787T3 (cs)
EE (1) EE04606B1 (cs)
ES (1) ES2208921T3 (cs)
HU (1) HUP9901794A3 (cs)
IL (2) IL127542A0 (cs)
IS (1) IS2216B (cs)
NO (1) NO323295B1 (cs)
NZ (1) NZ332990A (cs)
PL (1) PL189716B1 (cs)
PT (1) PT921787E (cs)
RS (1) RS49590B (cs)
RU (1) RU2203662C2 (cs)
SE (1) SE9602442D0 (cs)
SK (1) SK284204B6 (cs)
TR (1) TR199802647T2 (cs)
UA (1) UA64715C2 (cs)
WO (1) WO1997048380A1 (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
WO1999055158A1 (en) * 1998-04-30 1999-11-04 Sepracor Inc. S-rabeprazole compositions and methods
JP2002512262A (ja) * 1998-04-30 2002-04-23 セプラコール， インク． Ｒ−レイブプラゾール組成物及び方法
NZ510180A (en) 1998-08-10 2002-11-26 Univ California Prodrugs of the pyridyl-methylsulphonyl-benzimidazole type proton pump inhibitors
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
WO2000009092A1 (en) 1998-08-12 2000-02-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
US20050048077A1 (en) * 2002-02-21 2005-03-03 George Sachs Compositions, test kits and methods for detecting helicobacter pylori
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
AU6713194A (en) * 1993-04-27 1994-11-21 Sepracor, Inc. Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
JP3350054B2 (ja) * 1994-07-08 2002-11-25 アストラゼネカ・アクチエボラーグ 複数単位の錠剤化された剤形▲ｉ▼
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole

Also Published As

Publication number Publication date
DE69725860D1 (de) 2003-12-04
DE69725860T2 (de) 2004-09-09
AU3469097A (en) 1998-01-07
CA2257405A1 (en) 1997-12-24
IL127542A0 (en) 1999-10-28
UA64715C2 (en) 2004-03-15
TR199802647T2 (xx) 1999-03-22
RS49590B (sr) 2007-06-04
NO985964D0 (no) 1998-12-18
PL189716B1 (pl) 2005-09-30
IS4923A (is) 1998-12-15
PL330910A1 (en) 1999-06-07
HUP9901794A3 (en) 2002-11-28
EP0921787A1 (en) 1999-06-16
IL127542A (en) 2006-08-01
SK165598A3 (en) 1999-08-06
ATE252885T1 (de) 2003-11-15
EE9800435A (et) 1999-06-15
JP2000512993A (ja) 2000-10-03
WO1997048380A1 (en) 1997-12-24
NZ332990A (en) 2000-07-28
CZ420398A3 (cs) 2000-02-16
ES2208921T3 (es) 2004-06-16
US20050113418A1 (en) 2005-05-26
US20070276007A1 (en) 2007-11-29
BR9709838A (pt) 1999-08-10
AU726859B2 (en) 2000-11-23
IS2216B (is) 2007-03-15
PT921787E (pt) 2004-03-31
CN1222074A (zh) 1999-07-07
YU56698A (sh) 2004-12-31
SK284204B6 (sk) 2004-10-05
DK0921787T3 (da) 2004-02-23
EE04606B1 (et) 2006-04-17
HUP9901794A2 (hu) 2000-04-28
NO323295B1 (no) 2007-03-05
US20010008900A1 (en) 2001-07-19
CN1178648C (zh) 2004-12-08
EP0921787B1 (en) 2003-10-29
NO985964L (no) 1999-02-22
HK1018590A1 (en) 1999-12-30
RU2203662C2 (ru) 2003-05-10
CZ298213B6 (cs) 2007-07-25
US20090036494A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
SE9602442D0 (sv) Administration of pharmaceuticals
SE9704870D0 (sv) New pharmaceutical formulation I
IT1312377B1 (it) Composizioni a base di acido tiottico, cisteina e/o n-acetil cisteinada utilizzarsi in preparazioni farmaceutiche, dietetiche e cosmetiche
DK0869808T3 (da) Anvendelse af Glu-Trp-dipeptider til fremstilling af et lægemiddel til behandling af forskellige tilstande, der involverer neovaskularisation
DE69318503D1 (de) Ein definiertes lipidsystem enthaltende pharmazeutische zusammensetzung
AU3475097A (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
NZ244021A (en) Benzylthiazolidinedione derivatives, preparation and pharmaceutical compositions thereof
AP9701041A0 (en) Pyridylpyrrole compounds.
DE69033970D1 (de) Huperzin a analoge verbindungen
MX9800408A (es) Sales de derivados de amidina y de inhibidor de ciclooxigenasa, su procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
DK0736029T3 (da) Antikonvulsive pseudofructopyranosesulfamater
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
MY115795A (en) Substituted benzenesulfonylureas and -thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them
NO952234L (no) Transdermalt administreringsystem inneholdende acetylsalisylsyre for antitromboseterapi og forebygging av kreft
DE69412612D1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase
HUP9800623A2 (hu) (+)-O-demetil-tramadol felhasználása fájdalomcsillapító hatású orális gyógyszerkészítmények előállítására
NO974956L (no) Terapeutisk sammensetning for artritis
ATE269693T1 (de) Abführmittel und verfahren zu deren herstellung
PT777471E (pt) Metodo de inibicao da biosintese de leucotrieno
CO4180553A1 (es) Composiciones para el tratamiento de la peridontitis adulta
DK0615446T3 (da) Retard-lægemiddel indeholdende et dihydropyridinderivat i nanosolform og fremstilling heraf
JO1658B1 (en) New vehicles
MX9801680A (es) Derivado de fenil pirimidina opticamente activo como agente analgesico.